Overview

Fed Study of Balsalazide Disodium Capsules 750 mg and ColazalĀ® Capsules 750 mg

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan balsalazide disodium 750 mg capsules to Salix ColazalĀ® 750 mg capsules following a single, oral 2250 mg (3 x 750 mg) dose administration under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Balsalazide
Mesalamine